Previous Close | 10.62 |
Open | 10.64 |
Bid | 10.71 x 100 |
Ask | 10.77 x 100 |
Day's Range | 10.51 - 10.77 |
52 Week Range | 9.93 - 32.00 |
Volume | |
Avg. Volume | 433,475 |
Market Cap | 617.246M |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | 11.17 |
EPS (TTM) | 0.96 |
Earnings Date | May 10, 2024 - May 14, 2024 |
Forward Dividend & Yield | 0.60 (5.60%) |
Ex-Dividend Date | Feb 27, 2024 |
1y Target Est | 16.50 |
PARSIPPANY, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced its sponsorship of a symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference. This event is scheduled for Wednesday, March 6, at 10:40 a.m. Eastern Standard Time / 14:40 Central European Time. Additionally, six embecta-sponsored abstracts focusing on injection and insulin
Embecta Corp.'s ( NASDAQ:EMBC ) investors are due to receive a payment of $0.15 per share on 15th of March. This makes...
Embecta Corp. (NASDAQ:EMBC) Q1 2024 Earnings Call Transcript February 9, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $0.3497 EPS, expectations were $0.45. EMBC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome ladies and gentlemen to the […]